More fears for pharma IP rights in India as Novartis heads for the Supreme Court
India’s attitude towards pharmaceutical patents comes under the spotlight once again this week as Swiss multinational Novartis heads for the Supreme Court in Delhi in a last-ditch attempt to attain patent protection for its cancer drug Glivec…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.